GLP-1 Weight Loss and the Dietetic Monitoring Duty: When Does Muscle Loss Become a Negligence Question?

GLP-1 receptor agonists are now prescribed at a scale and pace that has, in some pathways, outstripped monitoring practice, particularly where prescribing happens online or through a pharmacy route with limited clinical oversight. Weight loss is typically judged by a single number on the scale. It should not be. A meaningful share of that weight is lean tissue, not fat, and where that loss goes unmonitored the consequences are measurable and, in some cases, preventable.

As an HCPC-registered dietitian, I am instructed in matters where the nutritional monitoring of a patient prescribed a GLP-1 medication is in issue, to assess the care provided, the standard against which it should be measured, and whether any shortfall caused or materially contributed to the harm alleged.

Why Lean Tissue Loss Is Clinically Significant

Across published trial data, lean tissue accounts for a substantial proportion of the weight lost on GLP-1 and dual agonist therapy, with estimates generally falling between one quarter and two fifths of total weight loss depending on the specific medication. In an older or frailer patient, or one with limited baseline muscle reserve, that loss is not incidental. It affects strength, mobility, glucose handling and the risk of falls, and it can offset much of the metabolic benefit the treatment was intended to deliver.

None of this makes GLP-1 therapy inappropriate. It makes proper monitoring, and where indicated, dietetic input on protein intake and resistance activity, part of the recognised standard of care rather than an optional extra.

What Inadequate Monitoring Looks Like

The failure patterns are consistent. A patient loses a rapid or substantial proportion of body weight with no baseline or follow-up assessment of what that weight loss is made of. No dietetic referral is made despite the rate or scale of loss meeting any reasonable threshold for concern. Dietary and activity advice, where given at all, is generic and unrelated to preserving lean tissue. In pathways where prescribing is remote or online, nutritional monitoring can be absent altogether, with the entire clinical relationship reduced to a prescription and a weigh-in.

The Consequences Can Be Measured

Where lean tissue loss has gone unaddressed, the consequences are largely objective. Reduced grip strength, functional decline, an unfavourable shift in body composition on DEXA or equivalent testing, and in some cases a fall or a fracture, are all demonstrable against the record. This is what allows a retrospective assessment of whether the nutritional monitoring met the recognised standard and whether any shortfall made a material difference.

The Analytical Framework: Standard, Breach, Causation

My analysis establishes what monitoring a competent prescribing pathway should have provided given the patient's starting point, the rate of weight loss and the presence of any recognised risk factors, whether the care provided met it, and, where it did not, what difference proper monitoring and dietetic input would have made, each anchored in the contemporaneous record.

Causation requires particular care here, because some lean tissue loss is an expected physiological feature of rapid weight reduction by any method, not evidence of negligence in itself. The expert must address, on the balance of probabilities, whether the loss sustained exceeds what would be expected with adequate monitoring and mitigation, and whether the absence of that monitoring was the reason it was not caught and addressed.

What a Dietitian Should Not Address

The decision to prescribe a GLP-1 medication, the choice of agent, and dose titration belong to the prescribing clinician. A dietetic report addresses nutritional monitoring, dietary and activity advice, and their absence or adequacy, and states clearly where that scope ends.

Practical Guidance for Instructing Solicitors

Records to obtain include: the prescribing record and any weight trend recorded at each review; any body composition or functional assessment carried out before or during treatment; the dietary and activity advice given, if any; and the referral pathway, including whether a dietetic referral was made or considered.

Key instruction questions: was the patient's baseline body composition or risk profile assessed before treatment began? Was monitoring proportionate to the rate and scale of weight loss recorded? Was a dietetic referral made when the threshold for one was met? And did any shortfall in monitoring cause or materially contribute to the harm alleged, as distinct from the expected physiological effect of the treatment itself?

Independent Dietitian Expert Witness

I provide independent expert witness opinion in clinical nutrition, including cases involving GLP-1 and other weight-management therapies, prepared to the standard required for court and within a clearly defined scope. You can learn more about my dietitian expert witness services or make an enquiry through rickmillerdietitian.co.uk.